UK markets close in 6 hours 47 minutes

Infinity Pharmaceuticals, Inc. (INFI)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.1800-0.0200 (-1.67%)
At close: 04:00PM EST
1.1700 -0.01 (-0.85%)
After hours: 04:03PM EST
Full screen
Trade prices are not sourced from all markets
Previous close1.2000
Open1.2500
Bid0.0000 x 2900
Ask0.0000 x 1800
Day's range1.1600 - 1.2800
52-week range1.0600 - 5.9800
Volume954,383
Avg. volume1,627,257
Market cap105.038M
Beta (5Y monthly)1.92
PE ratio (TTM)N/A
EPS (TTM)-0.5570
Earnings date14 Mar 2022 - 18 Mar 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est8.81
  • Business Wire

    Infinity Pharmaceuticals to Be Featured in a Fireside Chat as Part of B. Riley’s 2022 Virtual Oncology Conference

    CAMBRIDGE, Mass., January 20, 2022--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced that it will be highlighted during a virtual oncology fireside chat with B. Riley biotech research analyst Kalpit Patel on Thursday, January 27th at 10:30 am ET. The fireside chat will feature an interactive discussion with Infinity’s Executive Leadership Team,

  • Business Wire

    Infinity to Present at 40th Annual J.P. Morgan Healthcare Conference

    CAMBRIDGE, Mass., January 06, 2022--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced that Adelene Perkins, Chief Executive Officer, will give a corporate presentation at 7:30am ET on January 13, 2022 at the 40th annual J.P. Morgan Healthcare Conference, taking place virtually.

  • Business Wire

    Infinity Pharmaceuticals Outlines Eganelisib Clinical Development Strategy and Provides 2022 Guidance

    CAMBRIDGE, Mass., January 05, 2022--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today provided an update on eganelisib clinical development plans and 2022 guidance.